Roberto Pili

Genitourinary Section, Roswell Park Cancer Institute

Affiliated withRoswell Park Cancer Institute

Research Area

Biography

Roberto Pili has not added Biography.
If you are Roberto Pili and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 23	2014

Other Publications

Article	Year
Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer research\| PubMed ID: 11980632	2002
Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer cell\| PubMed ID: 12498716	2002
Is HIF-1 alpha a valid therapeutic target? Journal of the National Cancer Institute\| PubMed ID: 12671009	2003
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical model... Cancer research\| PubMed ID: 14522925	2003
A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research\| PubMed ID: 14980083	2004
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevac... Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15173063	2004
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhi... Cancer research\| PubMed ID: 15374977	2004
A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier. Bioconjugate chemistry\| PubMed ID: 15546210	2004
In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. The Prostate\| PubMed ID: 15651062	2005
A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjugate chemistry\| PubMed ID: 15656574	2005
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15867257	2005
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15958628	2005
Modeling the cost of management options for stage I nonseminomatous germ cell tumors: a decision tree analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 16110033	2005
A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical prostate cancer\| PubMed ID: 16197617	2005
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16428510	2006
Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. Journal of medicinal chemistry\| PubMed ID: 16640327	2006
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. American journal of clinical oncology\| PubMed ID: 16891869	2006
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 16943527	2006
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer research\| PubMed ID: 16951198	2006
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. The Prostate\| PubMed ID: 16955399	2006
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. Journal of pharmaceutical and biomedical analysis\| PubMed ID: 16971082	2007
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Molecular cancer therapeutics\| PubMed ID: 17237267	2007
Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer chemotherapy and pharmacology\| PubMed ID: 17256134	2007
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology\| PubMed ID: 17382158	2007
Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. The Prostate\| PubMed ID: 17520666	2007
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17634549	2007
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17671140	2007
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer biology & therapy\| PubMed ID: 17786033	2007
The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PloS one\| PubMed ID: 17786215	2007
Platelets take up the monoclonal antibody bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17855648	2007
Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. American journal of ophthalmology\| PubMed ID: 18054887	2008
Posttranscription regulation of prostate cancer growth. Cancer journal (Sudbury, Mass.)\| PubMed ID: 18303483	2008
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 18381951	2008
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18421048	2008
Symptoms, supportive care needs, and function in cancer patients: how are they related? Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation\| PubMed ID: 18493865	2008
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 18519793	2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18565882	2008
Reproducibility of tumor blood flow quantification with 15O-water PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 18832120	2008
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 19020076	2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 19047126	2008
Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer letters\| PubMed ID: 19111391	2009
VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo. Glycoconjugate journal\| PubMed ID: 19219548	2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 19487381	2009
Recent investigations of histone deacetylase inhibitors in renal cell carcinoma. Clinical advances in hematology & oncology : H&O\| PubMed ID: 19521328	2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer\| PubMed ID: 19536904	2009
NCCN clinical practice guidelines in oncology: testicular cancer. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 19555582	2009
NCCN clinical practice guidelines in oncology: kidney cancer. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 19555584	2009
Concordance of cancer patients' function, symptoms, and supportive care needs. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation\| PubMed ID: 19657724	2009
The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology\| PubMed ID: 19683801	2010
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department ... Cancer\| PubMed ID: 19711464	2009
Kidney cancer. Clinical practice guidelines. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 19813325	2005
Update on novel agents in renal cell carcinoma. Expert review of anticancer therapy\| PubMed ID: 19954293	2009
Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC cancer\| PubMed ID: 20122172	2010
Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation\| PubMed ID: 20340048	2010
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer chemotherapy and pharmacology\| PubMed ID: 20445979	2011
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20460477	2010
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational new drugs\| PubMed ID: 20499131	2011
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Molecular cancer therapeutics\| PubMed ID: 20501804	2010
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20978144	2010
Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free radical biology & medicine\| PubMed ID: 21078383	2011
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel, Switzerland)\| PubMed ID: 21151768	2010
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitin... Investigational new drugs\| PubMed ID: 21174224	2012
Is this a true renaissance for the treatment of prostate cancer? Oncology (Williston Park, N.Y.)\| PubMed ID: 21294477	2010
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 21335444	2011
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 21600760	2011
Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology\| PubMed ID: 21777963	2011
Development of a castrate resistant transplant tumor model of prostate cancer. The Prostate\| PubMed ID: 21796655	2012
Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells. Free radical biology & medicine\| PubMed ID: 21816220	2011
Provenge: combating prostate cancer with a vengeance? Expert review of vaccines\| PubMed ID: 21854304	2011
Kidney cancer. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 21917622	2011
Role of immunotherapy for renal cell cancer in 2011. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 21917625	2011
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 21931019	2011
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 21980135	2011
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cel... European journal of cancer (Oxford, England : 1990)\| PubMed ID: 22018713	2012
Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Molecular cancer therapeutics\| PubMed ID: 22084164	2012
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. PloS one\| PubMed ID: 22087262	2011
Resistance to angiogenesis inhibitors in renal cell carcinoma. Clinical advances in hematology & oncology : H&O\| PubMed ID: 22173604	2011
Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 22291088	2012
Pre-clinical models of renal carcinoma and their utility in drug development. Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.]\| PubMed ID: 22294393	2009
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PloS one\| PubMed ID: 22303460	2012
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 22409947	2012
Testicular cancer. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 22491049	2012
Mind the gap: potential for rebounds during antiangiogenic treatment breaks. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22679177	2012
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth in... BMC cancer\| PubMed ID: 22804960	2012
Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis\| PubMed ID: 22843200	2012
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences\| PubMed ID: 22917641	2012
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. The oncologist\| PubMed ID: 22971522	2012
Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology\| PubMed ID: 23162767	2012
Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer. Current oncology reports\| PubMed ID: 23334511	2013
Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. PloS one\| PubMed ID: 23671696	2013
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer journal (Sudbury, Mass.)\| PubMed ID: 23867515	2013
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clinical genitourinary cancer\| PubMed ID: 23891158	2013
Histone modifications: implications in renal cell carcinoma. Epigenomics\| PubMed ID: 23895657	2013
Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 23946170	2013
Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology\| PubMed ID: 24125689	2013
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget\| PubMed ID: 24163230	2013
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. The oncologist\| PubMed ID: 24309979	2014
Dietary protein restriction inhibits tumor growth in human xenograft models. Oncotarget\| PubMed ID: 24353195	2013
Kidney cancer, version 2.2014. Journal of the National Comprehensive Cancer Network : JNCCN\| PubMed ID: 24586079	2014
Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. OncoTargets and therapy\| PubMed ID: 24600234	2014